Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

The molecular study of IFNβ pleiotropic roles in MS treatment.

Kay M, Hojati Z, Dehghanian F.

Iran J Neurol. 2013;12(4):149-56. Review.

2.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
3.

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.

Mendes A, Sá MJ.

Arq Neuropsiquiatr. 2011 Jun;69(3):536-43. Review.

4.

Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.

J Manag Care Pharm. 2007 Apr;13(3):245-61.

5.

Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.

Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H.

Mult Scler. 2002 Dec;8(6):485-91.

PMID:
12474988
6.

Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.

Arbour N, Rastikerdar E, McCrea E, Lapierre Y, Dörr J, Bar-Or A, Antel JP.

Mult Scler. 2005 Dec;11(6):652-7.

PMID:
16320724
7.

Interferon-beta mechanisms of action in multiple sclerosis.

Dhib-Jalbut S, Marks S.

Neurology. 2010 Jan 5;74 Suppl 1:S17-24. doi: 10.1212/WNL.0b013e3181c97d99.

PMID:
20038758
8.

Stepped-care approach to treating MS: a managed care treatment algorithm.

Rich SR, Coleman IC, Cook R, Hum DS, Johnson B, Maves T, Mazanec WJ, Miller JR, Proveaux WJ, Rossman HS, Stuart WH.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S26-32. Review.

9.

Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.

Oleen-Burkey M, Cyhaniuk A, Swallow E.

J Med Econ. 2013;16(3):397-406. doi: 10.3111/13696998.2013.764309. Epub 2013 Jan 22.

PMID:
23301877
10.

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.

Chiao E, Meyer K.

Curr Med Res Opin. 2009 Jun;25(6):1445-54. doi: 10.1185/03007990902876040.

PMID:
19422279
11.
12.

Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.

Aharoni R.

J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. Review.

PMID:
24934599
13.

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Moses H Jr, Brandes DW.

Curr Med Res Opin. 2008 Sep;24(9):2679-90. doi: 10.1185/03007990802329959 . Epub 2008 Aug 8.

PMID:
18694542
14.

Immunomodulatory effects of interferon beta-1a in multiple sclerosis.

Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA.

J Neuroimmunol. 2001 Jan 1;112(1-2):153-62.

PMID:
11108944
15.

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Spelman T, Kalincik T, Zhang A, Pellegrini F, Wiendl H, Kappos L, Tsvetkova L, Belachew S, Hyde R, Verheul F, Grand-Maison F, Izquierdo G, Grammond P, Duquette P, Lugaresi A, Lechner-Scott J, Oreja-Guevara C, Hupperts R, Petersen T, Barnett M, Trojano M, Butzkueven H.

Ann Clin Transl Neurol. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27.

16.

Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.

Mahurkar S, Suppiah V, O'Doherty C.

Autoimmun Rev. 2014 Feb;13(2):178-86. doi: 10.1016/j.autrev.2013.10.012. Epub 2013 Nov 2. Review. Erratum in: Autoimmun Rev. 2014 Dec;13(12):1243.

PMID:
24189284
18.

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.

Reynolds MW, Stephen R, Seaman C, Rajagopalan K.

Curr Med Res Opin. 2010 Mar;26(3):663-74. doi: 10.1185/03007990903554257.

PMID:
20070144
19.

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

Stuart WH.

Curr Med Res Opin. 2007 Jun;23(6):1199-208. Epub 2007 Apr 23. Review.

PMID:
17559719
20.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135

Supplemental Content

Support Center